spacer
home > ebr > summer 2007 > manage risk, manage the regulator
PUBLICATIONS
European Biopharmaceutical Review

Manage Risk, Manage the Regulator

Risk management is the smart route to safety and well-aimed investment. In the increasingly competitive life sciences sector, Oliver Steck and Richard Petherick, at WCI Consulting Ltd, explain that picking up potential risks before they become a danger to the patient is imperative and has just been enforced by recent regulations

The traditional approach of pure compliance to regulations using a typically paperheavy system will probably keep you on the right side of the regulators – but, will it help you to improve your processes? The public demands a demonstrable increase in safety – no wonder the regulators are looking for a new approach! The traditional approach does not increase safety, nor does it deliver better or faster drug development, which ought to be one of the required outputs. Ultimately, the defect of the traditional approach is that, although it uses immense resources, it addresses the letter but not the spirit of regulations.

Shareholders are most likely to agree. Get caught putting profits before patient safety and nobody will trust you again. And trust is an issue that is right at the core of life sciences – once lost, trust is nearly impossible to recover.

FLEXIBILITY

The stakeholders seem to have a shared interest in a more flexible and sophisticated regulatory process. The industry must be ever aware of all its stakeholders. That includes patients, both those whose lives are being saved now and those yet to be saved. When everyone can see the point of a change, the law – patent, regulation – will follow. As a patient we want remedies that are effective, free of side effects, cheap and simple to use. The more serious our illness, the more important effectiveness becomes. The new, outcome-focused approach – where you are accountable for your serious adverse events (SAEs) whether technically compliant or not – is welcome in principle, but it needs to be backed by a systematic methodology.

That methodology is, without question, risk management and the accompanying IT – the smarter route to fewer adverse events (AEs), safer drugs and well aimed investment. But it is easy to do it superficially, endangering public safety, and regulators fear life science companies will use it as a shortcut to compliance. What it requires as a regulation tool is involvement and understanding from professional-level regulators rather than administration-level bureaucrats.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Oliver Steck is a Managing Consultant with WCI Consulting Ltd. Since joining the organisation three years ago, Oliver has helped life science clients optimise their processes with regards to content management, compliance-related issues and risk management. Oliver holds a degree in Medical Computer Science from the University of Heidelberg and the Polytechnic University Heilbronn.

Richard Petherick is a Senior Consultant with WCI Consulting Ltd. He has 10 years of experience working in the quality arena of the life science industry, both in manufacturing and corporate roles. Richard’s areas of expertise include regulatory compliance, risk management, project management and quality assurance.

spacer
Oliver Steck
spacer
spacer
spacer
Richard Petherick
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics Closes a $4.8 million USD (£3.7 million) Funding Round

Cambridge, UK, 10 June 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine® Single Cell Analysis System, expansion of the UK facility and enable the doubling of personnel through the opening of a new US Sales Office and Demo Lab in California.
More info >>

White Papers

Keeping Abreast of the Competitive Environment in Clinical Development

Thomson Reuters

Strategic management of a therapy area requires hard decisions to be made about which programs to invest in and which to let go. Understanding the rapidly changing competitive environment for your drug candidates is a key input into these decisions. It is easy to lose track of the broader picture when a clinical program is in progress and get blindsided by external events.
More info >>

 
Industry Events

BioPharm America™ 2019—12th Annual International Partnering Conference

11-12 September 2019, Boston Convention and Exhibition Center (BCEC), Boston, MA 02210 USA

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development. Life science executives from around the world gather to identify, meet and to enter into strategic relationships facilitated by partneringONE®, the world’s leading web-based partnering system. BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®. BioPharm America annually attracts 800+ delegates from over 500 companies who participated in 2,300+ scheduled one-to-one meetings. BioPharm America is now part of Biotech Week Boston, and together they draw a total of over 4,500 life science leaders, scientists and innovators.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement